485 related articles for article (PubMed ID: 25302162)
1. Review of the current targeted therapies for non-small-cell lung cancer.
Nguyen KS; Neal JW; Wakelee H
World J Clin Oncol; 2014 Oct; 5(4):576-87. PubMed ID: 25302162
[TBL] [Abstract][Full Text] [Related]
2. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
3. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
6. ALK inhibitors and advanced non-small cell lung cancer (review).
Rossi A; Maione P; Sacco PC; Sgambato A; Casaluce F; Ferrara ML; Palazzolo G; Ciardiello F; Gridelli C
Int J Oncol; 2014 Aug; 45(2):499-508. PubMed ID: 24889366
[TBL] [Abstract][Full Text] [Related]
7. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.
Sullivan I; Planchard D
Ther Adv Med Oncol; 2016 Jan; 8(1):32-47. PubMed ID: 26753004
[TBL] [Abstract][Full Text] [Related]
8. [News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
Hamard C; Ruppert AM; Lavole A; Rozensztajn N; Antoine M; Cadranel J; Wislez M
Ann Pathol; 2016 Jan; 36(1):63-72. PubMed ID: 26775573
[TBL] [Abstract][Full Text] [Related]
9. Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.
Facchinetti F; Tiseo M; Di Maio M; Graziano P; Bria E; Rossi G; Novello S
Transl Lung Cancer Res; 2016 Jun; 5(3):301-21. PubMed ID: 27413712
[TBL] [Abstract][Full Text] [Related]
10. Treating ALK-positive non-small cell lung cancer.
Ziogas DC; Tsiara A; Tsironis G; Lykka M; Liontos M; Bamias A; Dimopoulos MA
Ann Transl Med; 2018 Apr; 6(8):141. PubMed ID: 29862230
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies in development for non-small cell lung cancer.
Reungwetwattana T; Dy GK
J Carcinog; 2013; 12():22. PubMed ID: 24574860
[TBL] [Abstract][Full Text] [Related]
12. Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application.
Maione P; Sacco PC; Sgambato A; Casaluce F; Rossi A; Gridelli C
Ther Adv Med Oncol; 2015 Sep; 7(5):263-73. PubMed ID: 26327924
[TBL] [Abstract][Full Text] [Related]
13. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
Dong X; Fernandez-Salas E; Li E; Wang S
Neoplasia; 2016 Mar; 18(3):162-71. PubMed ID: 26992917
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
[TBL] [Abstract][Full Text] [Related]
15. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
16. [Current status of targeted therapy for anaplastic lymphoma kinase in non-small cell lung cancer].
Ma L; Zhang S
Zhongguo Fei Ai Za Zhi; 2014 Dec; 17(12):850-4. PubMed ID: 25539610
[TBL] [Abstract][Full Text] [Related]
17. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
18. Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
Miyawaki M; Yasuda H; Tani T; Hamamoto J; Arai D; Ishioka K; Ohgino K; Nukaga S; Hirano T; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
Mol Cancer Res; 2017 Jan; 15(1):106-114. PubMed ID: 27707887
[TBL] [Abstract][Full Text] [Related]
19. New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives.
de Mello RA; Neves NM; Tadokoro H; Amaral GA; Castelo-Branco P; Zia VAA
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33153004
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK.
Rothschild SI
Cancers (Basel); 2015 May; 7(2):930-49. PubMed ID: 26018876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
